Innohep (Tinzaparin)
Low Molecular Weight Heparin for Blood Clot Prevention
Innohep (tinzaparin sodium) is a low molecular weight heparin (LMWH) anticoagulant administered by injection. It is used to prevent blood clots (venous thromboembolism) in adults undergoing surgery, in acutely ill medical patients with restricted mobility, and to prevent clotting in the extracorporeal circuit during haemodialysis or haemofiltration. Tinzaparin works by enhancing the body's natural anticoagulant mechanisms, primarily through inhibition of Factor Xa.
Quick Facts
Key Takeaways
- Innohep (tinzaparin) is a low molecular weight heparin given by subcutaneous injection to prevent blood clots before and after surgery and in acutely ill patients.
- It is also used to prevent clotting in the extracorporeal circuit during haemodialysis or haemofiltration.
- Innohep must not be used in patients with active bleeding, bacterial endocarditis, cerebral haemorrhage, or bleeding peptic ulcers.
- The multi-dose vial contains benzyl alcohol and must not be used in neonates, premature infants, or children under 3 years. Pregnant women should use pre-filled syringes without benzyl alcohol.
- Routine coagulation monitoring is generally not required, but anti-Xa levels may be checked in patients with renal impairment, extremes of body weight, or during pregnancy.
What Is Innohep and What Is It Used For?
Quick Answer: Innohep (tinzaparin) is an injectable anticoagulant belonging to the low molecular weight heparin class. It prevents blood clots by inhibiting specific clotting factors in the blood, and is used in surgical prophylaxis, medical prophylaxis in acutely ill patients, and during haemodialysis.
Innohep contains the active substance tinzaparin sodium, a low molecular weight heparin (LMWH) derived from unfractionated heparin through controlled enzymatic depolymerisation. LMWHs have largely replaced unfractionated heparin in many clinical settings due to their more predictable pharmacokinetic profile, higher bioavailability after subcutaneous injection, and reduced need for laboratory monitoring.
Tinzaparin exerts its anticoagulant effect primarily by binding to antithrombin III (AT III), a naturally occurring inhibitor of coagulation. This binding dramatically accelerates the rate at which antithrombin III inactivates Factor Xa, a key enzyme in the coagulation cascade responsible for converting prothrombin to thrombin. By inhibiting Factor Xa, tinzaparin disrupts the amplification of the clotting cascade, preventing the formation of fibrin and ultimately the development of blood clots. Tinzaparin also inhibits thrombin (Factor IIa) to a lesser extent, with an anti-Xa to anti-IIa ratio of approximately 1.5:1.
Approved Indications
Innohep is approved for use in the following clinical settings:
- Surgical thromboprophylaxis: Prevention of venous thromboembolism (VTE) in adults undergoing general surgery, orthopaedic surgery (such as hip or knee replacement), or other surgical procedures associated with an increased risk of blood clot formation. Treatment is typically initiated before surgery and continued during the postoperative period of reduced mobility.
- Medical thromboprophylaxis: Prevention of blood clots in acutely ill adult patients who have an increased risk of VTE due to acute medical conditions combined with significantly reduced mobility, such as patients hospitalised with heart failure, severe respiratory disease, or acute infectious illness.
- Extracorporeal circuit anticoagulation: Prevention of clot formation within the tubing and dialyser membrane during haemodialysis or haemofiltration procedures. During these treatments, blood passes through an external circuit where it is filtered by a dialysis machine acting as an artificial kidney. Without anticoagulation, the blood would clot within this circuit, making the treatment ineffective.
Your prescribing physician may use Innohep for other clinical purposes based on their professional judgement. In such cases, follow your doctor's specific instructions regarding dosage and duration of treatment. In many countries, LMWHs including tinzaparin are also used for the treatment (not just prevention) of established deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in the context of cancer-associated thrombosis, where international guidelines from the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Clinical Oncology (ASCO) recommend LMWHs as a preferred option.
Unlike oral anticoagulants such as warfarin (which inhibits vitamin K-dependent clotting factors) or direct oral anticoagulants (DOACs) like rivaroxaban and apixaban (which directly inhibit Factor Xa), Innohep must be administered by injection. However, its predictable dose-response and rapid onset of action make it particularly valuable in the perioperative setting, during pregnancy (where oral anticoagulants may be contraindicated), and in patients with cancer-associated thrombosis.
What Should You Know Before Using Innohep?
Quick Answer: Innohep must not be used if you have an increased risk of uncontrolled bleeding, bacterial endocarditis, cerebral haemorrhage, or active peptic ulcers. Special caution is required in patients with kidney impairment, low platelet counts, or those receiving spinal anaesthesia. The multi-dose vial must never be given to neonates or premature infants.
Contraindications
You must not use Innohep in the following circumstances:
- Increased bleeding risk: Any condition associated with a heightened risk of generalised or localised bleeding, including active haemorrhage that cannot be controlled.
- Bacterial endocarditis: An infection of the heart valves, where anticoagulation could precipitate life-threatening bleeding from infected vegetation on the valves.
- Cerebral haemorrhage: Recent or current bleeding within the brain, where anticoagulation could worsen the haemorrhage and cause further neurological damage.
- Active peptic ulcer: A bleeding or recently bleeding gastric or duodenal ulcer, where anticoagulation could trigger or worsen gastrointestinal haemorrhage.
- Allergy to tinzaparin: Known hypersensitivity to tinzaparin sodium, heparin, or any of the other ingredients in the formulation (listed in the composition section).
- Neonates and premature infants: The multi-dose vial formulation contains benzyl alcohol as a preservative, which is toxic to neonates and premature infants and has been associated with fatal “gasping syndrome.”
Warnings and Precautions
Talk to your doctor or pharmacist before using Innohep if any of the following apply to you:
- Severe renal impairment: Tinzaparin is primarily cleared by the kidneys. In patients with significantly reduced kidney function, the drug may accumulate, leading to an increased risk of bleeding. Your doctor may need to monitor anti-Xa levels and adjust your dose accordingly. This is particularly important in elderly patients, who are more likely to have age-related decline in kidney function.
- Thrombocytopenia (low platelet count): All heparins, including LMWHs, carry a risk of heparin-induced thrombocytopenia (HIT), a serious immune-mediated condition where antibodies against heparin-platelet factor 4 complexes cause platelet activation and paradoxical thrombosis. Platelet counts should be monitored, especially during the first few weeks of treatment. If a significant drop in platelet count occurs, Innohep must be discontinued immediately and an alternative anticoagulant initiated.
- Diabetes mellitus: Heparins can affect aldosterone secretion, potentially leading to elevated potassium levels (hyperkalaemia). Patients with diabetes may be at increased risk, particularly those with pre-existing renal impairment or those taking potassium-sparing medications.
- Asthma: Caution is advised in patients with asthma, as heparin products have occasionally been associated with bronchospasm.
- Elevated blood potassium: If you already have hyperkalaemia or are taking medications that raise potassium levels, your doctor should monitor your electrolytes during Innohep treatment.
- Mechanical heart valve prosthesis: Patients with prosthetic heart valves require carefully managed anticoagulation. Innohep has not been adequately studied in this population, and its use requires specialist supervision.
If you are scheduled for a spinal or epidural procedure (lumbar puncture, spinal anaesthesia, or epidural anaesthesia), there must be a minimum interval of 12 hours between the last Innohep injection and the procedure. After the procedure is completed, Innohep should not be administered for at least 4–6 hours. Patients receiving Innohep who undergo spinal or epidural procedures must be closely monitored for signs of spinal cord compression, including muscle weakness, numbness, or loss of bowel/bladder control. This rare but serious complication (epidural or spinal haematoma) can result in permanent paralysis if not detected and treated promptly.
Innohep should not be injected into muscle tissue (intramuscular injection). Due to the risk of subcutaneous bleeding (haematoma), other medications that are normally given by intramuscular injection should also be avoided during Innohep treatment.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, are planning to become pregnant, or are breastfeeding, consult your doctor or pharmacist before using this medicine.
Pregnancy: Treatment of blood clots during pregnancy requires the involvement of a specialist physician experienced in anticoagulation management. Innohep can be used throughout pregnancy if your doctor determines it is medically necessary. Tinzaparin does not cross the placenta, which is a significant advantage over oral anticoagulants such as warfarin (which are teratogenic and can cause fetal bleeding).
However, pregnant women with mechanical heart valve prostheses should not use Innohep, as adequate efficacy data are not available for this high-risk population. The multi-dose vial formulation contains benzyl alcohol, which can cross the placenta. Therefore, pregnant women should use pre-filled syringes (which do not contain benzyl alcohol) rather than the multi-dose vial.
Breastfeeding: It is not known whether tinzaparin is excreted into human breast milk. However, LMWHs are large molecules with poor oral bioavailability, making significant absorption by a nursing infant unlikely. Consult your doctor before using Innohep while breastfeeding.
Fertility: No clinical studies have been conducted to assess the effect of tinzaparin on human fertility.
Use in Children
The multi-dose vial formulation of Innohep contains the preservative benzyl alcohol. This preservative must not be given to premature infants or neonates, as it can cause toxic reactions and severe allergic responses. It should also not be given to children under 3 years of age unless specifically recommended by a doctor. Benzyl alcohol has been associated with serious adverse events in young children, including a fatal condition known as “gasping syndrome,” characterised by respiratory distress, metabolic acidosis, and cardiovascular collapse.
Driving and Operating Machinery
Innohep has no or negligible effect on the ability to drive or operate machinery. You may continue to drive and use machines as normal during treatment.
How Does Innohep Interact with Other Drugs?
Quick Answer: Innohep can interact with other blood-thinning medications, NSAIDs, and certain other drugs, increasing the risk of bleeding. Always inform your doctor about all medications you are taking, including over-the-counter medicines and supplements.
Since Innohep reduces the blood's ability to clot, combining it with other medications that also affect blood clotting or platelet function can significantly increase the risk of bleeding. It is essential to inform your doctor or pharmacist about all medicines you are currently using, have recently used, or might use.
Major Interactions
The following drug combinations with Innohep carry a significant risk of increased bleeding and should generally be avoided or used only under close medical supervision:
| Drug / Drug Class | Interaction | Clinical Significance |
|---|---|---|
| NSAIDs (aspirin, ibuprofen, naproxen, diclofenac) | Inhibit platelet aggregation and may irritate the gastric mucosa, increasing the risk of gastrointestinal bleeding | High – Avoid combination unless specifically directed by your doctor |
| Thrombolytics (alteplase, streptokinase, tenecteplase) | Dissolve existing blood clots while Innohep prevents new clot formation, creating a greatly increased bleeding risk | High – Close monitoring required in acute settings only |
| Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon) | Both drugs inhibit the coagulation cascade through different mechanisms, leading to additive anticoagulant effects | High – Bridging protocols require careful INR monitoring during overlap |
| Direct oral anticoagulants (rivaroxaban, apixaban, edoxaban, dabigatran) | Direct Factor Xa or thrombin inhibitors combined with Innohep cause dual anticoagulation | High – Avoid concurrent use; switching between agents requires appropriate washout |
| Activated protein C (drotrecogin alfa) | Additional anticoagulant effect when combined with heparins | High – Use only under specialist supervision |
Minor Interactions
The following interactions are less clinically significant but should still be discussed with your doctor:
- Antiplatelet agents (clopidogrel, ticagrelor, prasugrel): Additive inhibition of platelet function when combined with Innohep. Dual therapy may be clinically necessary in certain cardiovascular conditions but requires careful risk-benefit assessment.
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): These antidepressants can impair platelet function, potentially increasing bleeding risk when combined with anticoagulants.
- Dextran: This plasma expander has antiplatelet properties and may increase bleeding risk when given alongside Innohep.
- Potassium-sparing diuretics and ACE inhibitors: All heparins can suppress aldosterone, potentially increasing serum potassium. This risk is enhanced by concomitant use of medications that also raise potassium levels.
What Is the Correct Dosage of Innohep?
Quick Answer: Innohep dosage varies depending on the indication. For surgical thromboprophylaxis, a fixed dose is typically given once daily by subcutaneous injection. For dialysis, the dose is administered into the extracorporeal circuit. Your doctor will determine the correct dose based on your weight and clinical situation.
Always use Innohep exactly as your doctor has instructed. Do not change your dose without consulting your doctor. Your doctor may perform blood tests (such as anti-Xa levels) to evaluate the effectiveness and safety of your treatment, particularly if you have renal impairment or other risk factors.
Adults – Surgical and Medical Thromboprophylaxis
Subcutaneous Injection
Innohep is injected under the skin (subcutaneous injection), typically into the fatty tissue of the abdominal wall. The dose and duration of treatment depend on the type of surgery or medical condition:
- General surgery (moderate VTE risk): 3,500 anti-Xa IU once daily, starting 2 hours before surgery and continuing for 7–10 days or until the patient is fully mobile.
- Orthopaedic surgery (high VTE risk): 50 anti-Xa IU per kilogram of body weight once daily, or 4,500 anti-Xa IU once daily, starting 12 hours before surgery and continuing for 7–10 days or as directed by your surgeon.
- Acutely ill medical patients: The dose is determined by your doctor based on your individual risk factors, body weight, and clinical condition.
Haemodialysis and Haemofiltration
Extracorporeal Circuit
For prevention of clotting during haemodialysis or haemofiltration, Innohep is injected into the arterial line of the dialysis machine or directly into a vein. The dose depends on the duration of the dialysis session:
- Sessions up to 4 hours: A single bolus injection of approximately 2,000–2,500 anti-Xa IU into the arterial line at the start of dialysis.
- Sessions longer than 4 hours: An initial bolus of approximately 2,500 anti-Xa IU, followed by a maintenance infusion of approximately 750 anti-Xa IU per hour.
Doses are adjusted based on the patient's response and any observed clotting in the extracorporeal circuit. Your dialysis team will manage this dosing.
The multi-dose vial formulation (10,000 anti-Xa IU/mL) is intended for hospital use and is administered by doctors or nurses. Patients who need to self-inject at home are typically prescribed pre-filled syringes with pre-measured doses.
Elderly Patients
Elderly patients, particularly those over 75 years of age, may have reduced kidney function that is not reflected in standard blood tests (serum creatinine). Since tinzaparin is primarily excreted by the kidneys, drug accumulation and an increased risk of bleeding may occur. Your doctor may estimate your kidney function using calculated creatinine clearance and may monitor anti-Xa levels to ensure safe and effective dosing.
Missed Dose
If you forget to use Innohep at the scheduled time, take it as soon as you remember, provided it is not too close to the time of your next scheduled dose. Do not take a double dose to make up for a missed injection. If you are unsure what to do, contact your doctor or pharmacist for advice.
Overdose
If too much Innohep has been administered, or if a child has accidentally received the medicine, contact your doctor, hospital, or poison control centre immediately for assessment. An overdose of Innohep can result in bleeding, which may range from minor bruising to serious haemorrhage. The anticoagulant effect of tinzaparin can be partially reversed with protamine sulfate, although protamine is more effective at neutralising the anti-IIa activity than the anti-Xa activity of LMWHs.
What Are the Side Effects of Innohep?
Quick Answer: Common side effects include injection site reactions, bleeding, skin redness, and anaemia. Uncommon side effects include changes in platelet count, hypersensitivity, and transient liver enzyme elevations. Rare but serious side effects include angioedema, severe allergic reactions, skin necrosis, and osteoporosis with prolonged use.
Like all medicines, Innohep can cause side effects, although not everyone experiences them. Most side effects are mild and resolve on their own. However, some side effects require immediate medical attention.
Stop using Innohep and contact your doctor immediately if you experience any of the following:
- Angioedema (affects up to 1 in 1,000 people): Swelling of the face, tongue, or throat; difficulty swallowing; hives and breathing difficulties.
- Severe allergic skin reaction (affects up to 1 in 1,000 people): An extremely severe allergic reaction with skin rash, typically in the form of blisters or sores in the mouth, eyes, and other mucous membranes.
Side Effects by Frequency
Common
Affects up to 1 in 10 people
- Injection site reactions (pain, itching, swelling, bruising)
- Bleeding (at various sites)
- Skin redness (erythema)
- Anaemia (low red blood cell count)
Uncommon
Affects up to 1 in 100 people
- Increased or decreased platelet count (thrombocytosis or thrombocytopenia)
- Hypersensitivity reactions
- Bruising (ecchymosis)
- Skin redness and flushing
- Transient liver enzyme elevations
- Skin rash
- Dermatitis (skin inflammation)
- Pruritus (itching)
Rare
Affects up to 1 in 1,000 people
- Allergic reactions (anaphylactoid reactions)
- Urticaria (hives)
- Skin necrosis (localised tissue death at injection site)
- Osteoporosis (bone thinning with prolonged use)
- Hyperkalaemia (elevated potassium levels in the blood)
- Priapism (painful persistent erection)
Heparin-Induced Thrombocytopenia (HIT)
A particularly important adverse effect associated with all heparin products, including tinzaparin, is heparin-induced thrombocytopenia (HIT). HIT is an immune-mediated condition in which antibodies form against complexes of heparin and platelet factor 4 (PF4). These antibodies activate platelets, paradoxically leading to a hypercoagulable state with both thrombocytopenia and an increased risk of arterial and venous thrombosis. HIT typically occurs 5–14 days after starting heparin therapy.
According to guidelines from the American Society of Hematology (ASH) and the British Society for Haematology (BSH), a platelet count drop of 50% or more from baseline, or a new thrombotic event during heparin therapy, should raise suspicion for HIT. If HIT is suspected, all heparin products must be stopped immediately and an alternative non-heparin anticoagulant (such as argatroban, bivalirudin, or fondaparinux) should be initiated. The risk of HIT is lower with LMWHs compared to unfractionated heparin, but it remains a clinically important concern.
Reporting Side Effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any side effects not listed above. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you can help provide more information about the safety of this medicine.
How Should You Store Innohep?
Quick Answer: Store Innohep out of the sight and reach of children. No special storage temperature is required. Once opened, the multi-dose vial can be stored for up to 28 days at up to 30°C. Do not use if the solution is cloudy or contains visible particles.
Proper storage of Innohep is essential to maintain its effectiveness and safety. Follow these storage guidelines:
- Keep out of the sight and reach of children at all times.
- No special storage conditions are required for unopened vials. The product can be stored at room temperature.
- Once opened: The chemical and physical stability of the multi-dose vial has been demonstrated for 28 days at up to 30°C. From a microbiological standpoint, the opened vial may be stored for a maximum of 28 days at 30°C. Any remaining product should be discarded after this period.
- Do not use after the expiry date printed on the carton. The expiry date refers to the last day of the stated month.
- Do not use if the injection solution appears cloudy or if visible particles or precipitation can be observed. A slight yellow discolouration during storage is normal and does not affect the product's safety or efficacy.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help protect the environment.
What Does Innohep Contain?
Quick Answer: The active substance is tinzaparin sodium at a concentration of 10,000 anti-Xa IU/mL (equivalent to 120 mg tinzaparin per mL). The multi-dose vial also contains benzyl alcohol as a preservative, along with sodium acetate trihydrate and other excipients.
Active Substance
Each millilitre of Innohep solution for injection contains tinzaparin sodium 10,000 anti-Xa IU (equivalent to 120 mg tinzaparin). IU stands for International Units, the standardised measurement for anticoagulant potency of heparin products.
Other Ingredients (Excipients)
- Sodium acetate trihydrate – buffer to maintain pH
- Sodium hydroxide – for pH adjustment
- Hydrochloric acid, concentrated – for pH adjustment
- Water for injections – solvent
- Benzyl alcohol – preservative (10 mg per mL in the multi-dose vial formulation)
This medicine contains 10 mg benzyl alcohol per mL. Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been associated with serious side effects including breathing problems (“gasping syndrome”) in young children. Do not use for more than one week in children under 3 years unless advised by your doctor. If you are pregnant or breastfeeding, consult your doctor before use, as large amounts of benzyl alcohol can accumulate in the body and cause side effects (metabolic acidosis). If you have impaired liver or kidney function, consult your doctor before use.
This medicine contains less than 1 mmol sodium (23 mg) per mL, i.e. it is essentially sodium-free.
Appearance and Pack Sizes
Innohep is a colourless to slightly yellow solution supplied in glass vials with rubber stoppers. Available pack sizes include:
- 10,000 anti-Xa IU/mL: 10 × 2 mL vials
- 10,000 anti-Xa IU/mL: 10 × 5 mL vials
Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Innohep
Innohep (tinzaparin) is a low molecular weight heparin used to prevent blood clots (thromboprophylaxis) in adults before and after surgery, to prevent blood clots in acutely ill medical patients with reduced mobility, and to prevent clotting in the extracorporeal circuit during haemodialysis or haemofiltration. It works by inhibiting blood coagulation factors, primarily Factor Xa, through enhancement of antithrombin III activity.
Innohep is administered as a subcutaneous injection (under the skin), typically into the abdominal wall. For dialysis patients, it is injected into the arterial line of the dialysis circuit or directly into a vein. The multi-dose vial formulation is intended for hospital use and is administered by healthcare professionals. Your doctor will determine the correct dose based on your body weight and clinical situation.
The most common side effects of Innohep include injection site reactions (pain, itching, swelling, bruising), bleeding, skin redness, and anaemia. These occur in up to 1 in 10 people. Less common side effects include changes in platelet count, hypersensitivity reactions, bruising (ecchymosis), rash, and transient liver enzyme elevation. Rare but serious effects include angioedema and severe allergic reactions. Seek immediate medical attention if you experience swelling of the face or throat, difficulty breathing, or widespread blistering.
Innohep may be used during pregnancy if your doctor determines it is medically necessary. Tinzaparin does not cross the placenta, making it a safer option than oral anticoagulants like warfarin during pregnancy. However, the multi-dose vial formulation contains benzyl alcohol, which can cross the placenta, so pre-filled syringes (without benzyl alcohol) should be used during pregnancy. Pregnant women with mechanical heart valve prostheses should not use Innohep. Treatment of thrombosis during pregnancy should always involve a specialist physician.
Innohep (tinzaparin) is a low molecular weight heparin (LMWH), which differs from unfractionated heparin in having a more predictable dose-response, longer half-life, and higher bioavailability after subcutaneous injection. Unlike oral anticoagulants such as warfarin or direct oral anticoagulants (DOACs like rivaroxaban and apixaban), Innohep must be given by injection. LMWHs are preferred in certain clinical situations including cancer-associated thrombosis, pregnancy, and perioperative prophylaxis due to their reliable pharmacokinetics and established safety profile.
Routine coagulation monitoring is generally not required for Innohep at standard prophylactic doses. This is one advantage over unfractionated heparin, which requires regular aPTT monitoring. However, your doctor may order anti-Xa level monitoring in certain patients, such as those with severe renal impairment, very low or very high body weight, pregnant patients, or elderly patients with reduced kidney function. Platelet counts may also be monitored during the first few weeks of treatment to detect heparin-induced thrombocytopenia (HIT).
References
This article is based on the following peer-reviewed sources, international guidelines, and authoritative medical references:
- European Medicines Agency (EMA). Innohep – Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543–603. doi:10.1093/eurheartj/ehz405
- National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline [NG89]. 2018. Available at: www.nice.org.uk/guidance/ng89
- Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226–3256. doi:10.1182/bloodadvances.2018024828
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–3392. doi:10.1182/bloodadvances.2018024489
- Bates SM, Rajasekhar A, Engel B, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e351S–e418S.
- British National Formulary (BNF). Tinzaparin sodium. Available at: bnf.nice.org.uk
- Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153. doi:10.1056/NEJMoa025313
Editorial Team
This article was written by the iMedic Medical Editorial Team, comprising licensed physicians specialising in haematology, internal medicine, and clinical pharmacology. All content is reviewed according to international medical guidelines and the GRADE evidence framework.
Reviewed by board-certified specialists in haematology and clinical pharmacology with expertise in anticoagulation therapy and venous thromboembolism management.
Evidence Level 1A. Based on systematic reviews, international guidelines (ESC, ISTH, ACCP, NICE, ASH), and peer-reviewed clinical trials. No commercial funding or pharmaceutical sponsorship.